Interleukin-35 Limits Anti-Tumor Immunity

Immunity

Volumn 44, Issue 2, 2016, Pages 316-329

  Turnis, Meghan E ^b   Sawant, Deepali V ^a,b   Szymczak Workman, Andrea L ^a,b   Andrews, Lawrence P ^a   Delgoffe, Greg M ^b,c   Yano, Hiroshi ^a   Beres, Amy J ^b,d   Vogel, Peter ^b   Workman, Creg J ^a,b   Vignali, Dario A A ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Immucor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 35; NEUTRALIZING ANTIBODY; NUCLEAR RECEPTOR NUR77; PROTEIN LAG3; PROTEIN PD1; PROTEIN TIM3; RECEPTOR; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CD223 ANTIGEN; HAVCR2 PROTEIN, MOUSE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, MOUSE; LEUKOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON ADENOCARCINOMA; CONTROLLED STUDY; IMMUNOLOGICAL MEMORY; LUNG METASTASIS; MELANOMA B16; MEMORY T LYMPHOCYTE; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL GROWTH; CELL PROLIFERATION; DRUG EFFECTS; EXPERIMENTAL MELANOMA; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; SKIN TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL PROLIFERATION; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, VIRUS; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 84958107720     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2016.01.013     Document Type: Article

References (38)

1. Bettini M., Castellaw A.H., Lennon G.P., Burton A.R., Vignali D.A. Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. Diabetes 2012, 61:1519-1526.
2. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., Betts M.R., Freeman G.J., Vignali D.A., Wherry E.J. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
3. Brooks D.G., Ha S.J., Elsaesser H., Sharpe A.H., Freeman G.J., Oldstone M.B. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. USA 2008, 105:20428-20433.
4. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol. Res. 2010, 46:79-93.
5. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., Cross R., Sehy D., Blumberg R.S., Vignali D.A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
6. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., Finkelstein D., Forbes K., Workman C.J., Brown S.A., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11:1093-1101.
7. Delgoffe G.M., Woo S.R., Turnis M.E., Gravano D.M., Guy C., Overacre A.E., Bettini M.L., Vogel P., Finkelstein D., Bonnevier J., et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 2013, 501:252-256.
8. DuPage M., Dooley A.L., Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 2009, 4:1064-1072.
9. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., von Herrath M.G. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 2006, 203:2461-2472.
10. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
11. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., Zlobec I., Hartmann A., Bifulco C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 2014, 232:199-209.
12. Gonin J., Larousserie F., Bastard C., Picquenot J.M., Couturier J., Radford-Weiss I., Dietrich C., Brousse N., Vacher-Lavenu M.C., Devergne O. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS ONE 2011, 6:e24617.
13. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
14. Kaufmann D.E., Kavanagh D.G., Pereyra F., Zaunders J.J., Mackey E.W., Miura T., Palmer S., Brockman M., Rathod A., Piechocka-Trocha A., et al. Upregulation of CTLA-by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 2007, 8:1246-1254.
15. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8:191-197.
16. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.
17. Long J., Zhang X., Wen M., Kong Q., Lv Z., An Y., Wei X.Q. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem. Biophys. Res. Commun. 2013, 430:364-369.
18. Long A.H., Haso W.M., Shern J.F., Wanhainen K.M., Murgai M., Ingaramo M., Smith J.P., Walker A.J., Kohler M.E., Venkateshwara V.R., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 2015, 21:581-590.
19. Moran A.E., Holzapfel K.L., Xing Y., Cunningham N.R., Maltzman J.S., Punt J., Hogquist K.A. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 2011, 208:1279-1289.
20. Nakamoto N., Kaplan D.E., Coleclough J., Li Y., Valiga M.E., Kaminski M., Shaked A., Olthoff K., Gostick E., Price D.A., et al. Functional restoration of HCV-specific CD8 T cells by PD-blockade is defined by PD-expression and compartmentalization. Gastroenterology 2008, 134:1927-1937. 1937 e1921-1922.
21. Nishikawa H., Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 2014, 27:1-7.
22. Nishino R., Takano A., Oshita H., Ishikawa N., Akiyama H., Ito H., Nakayama H., Miyagi Y., Tsuchiya E., Kohno N., et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin. Cancer Res. 2011, 17:6272-6286.
23. Ohkura N., Kitagawa Y., Sakaguchi S. Development and maintenance of regulatory T cells. Immunity 2013, 38:414-423.
24. Olson B.M., Jankowska-Gan E., Becker J.T., Vignali D.A., Burlingham W.J., McNeel D.G. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-or IL-35 blockade. J. Immunol. 2012, 189:5590-5601.
25. Page D.B., Postow M.A., Callahan M.K., Allison J.P., Wolchok J.D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014, 65:185-202.
26. Paley M.A., Kroy D.C., Odorizzi P.M., Johnnidis J.B., Dolfi D.V., Barnett B.E., Bikoff E.K., Robertson E.J., Lauer G.M., Reiner S.L., Wherry E.J. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
27. Penaloza-MacMaster P., Kamphorst A.O., Wieland A., Araki K., Iyer S.S., West E.E., O'Mara L., Yang S., Konieczny B.T., Sharpe A.H., et al. Interplay between regulatory T cells and PD-in modulating T cell exhaustion and viral control during chronic LCMV infection. J. Exp. Med. 2014, 211:1905-1918.
28. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., Fontenot J., Castelli L., Ye X., Treuting P., Siewe L., Roers A., Henderson W.R., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28:546-558.
29. Senovilla L., Vacchelli E., Galon J., Adjemian S., Eggermont A., Fridman W.H., Sautès-Fridman C., Ma Y., Tartour E., Zitvogel L., et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. OncoImmunology 2012, 1:1323-1343.
30. Shen P., Roch T., Lampropoulou V., O'Connor R.A., Stervbo U., Hilgenberg E., Ries S., Dang V.D., Jaimes Y., Daridon C., et al. 35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases 2014, Nature, IL.
31. Tinoco R., Alcalde V., Yang Y., Sauer K., Zuniga E.I. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009, 31:145-157.
32. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
33. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 2002, 188:122-135.
34. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
35. Wang Z., Liu J.Q., Liu Z., Shen R., Zhang G., Xu J., Basu S., Feng Y., Bai X.F. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J. Immunol. 2013, 190:2415-2423.
36. Wang R.X., Yu C.R., Dambuza I.M., Mahdi R.M., Dolinska M.B., Sergeev Y.V., Wingfield P.T., Kim S.H., Egwuagu C.E. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 2014, 20:633-641.
37. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., Subramaniam S., Blattman J.N., Barber D.L., Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
38. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-and PD-synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012, 72:917-927.